InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
InflaRx presented new pre-clinical data on oral C5aR1 antagonist izicopan at ASN Kidney Week 2026, showing renal protection in two hamster models of kidney injury. In both ischemia-reperfusion injury and obstructive nephropathy models, izicopan significantly reduced markers of renal injury (BUN and creatinine, p < 0.001) versus vehicle controls. Structural modeling suggests izicopan avoids the CYP3A4/5 time-dependent inhibition seen with avacopan, supporting a differentiated, potentially best-in-class profile.
Key figures
- Drug Name
- izicopan
- Phase Of Trial
- Pre-clinical (animal models)
- Doses tested
- 100 mg/kg single oral dose (IRI); 14-day oral dosing (UUO)
- Phase1 dose range
- 3 mg to 240 mg single doses; 30-90 mg twice daily multiple doses
- P value bun creatinine
- p < 0.001
- C5a neutrophil blockade
- ≥90% over 14-day dosing
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.